Year All 2026 2025 2024 2023 2021 Nov 18, 2026 Iambic Presents Preclinical Data for CDK2/4 Inhibitor IAM-C1 and Brain-Penetrant KIF18A Inhibitor IAM217 at 2026 EORTC-NCI-AACR Symposium Read More Nov 16, 2026 Iambic Provides Business Updates and Third Quarter 2026 Financial Results Read More Nov 09, 2026 Iambic to participate in Jefferies Global Healthcare Conference Read More Oct 26, 2026 Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers Read More Oct 14, 2026 Iambic Announces Pricing of Initial Public Offering Read More Oct 05, 2026 Iambic Submits IND for a Potentially Brain-Penetrant KIF18A Inhibitor IAM217, Its Second Wholly Owned AI-Discovered Candidate Read More Sep 21, 2026 Iambic Launches Enchant v3 – Molecular Superintelligence Designed to Advance End-to-End Drug Discovery & Development Read More Sep 21, 2026 AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery Read More Jun 22, 2026 Bayer and Iambic collaborate to advance drug discovery with AI Read More May 19, 2026 Iambic Named to CNBC Disruptor 50 for Second Consecutive Year Read More
Nov 18, 2026 Iambic Presents Preclinical Data for CDK2/4 Inhibitor IAM-C1 and Brain-Penetrant KIF18A Inhibitor IAM217 at 2026 EORTC-NCI-AACR Symposium Read More
Oct 26, 2026 Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers Read More
Oct 05, 2026 Iambic Submits IND for a Potentially Brain-Penetrant KIF18A Inhibitor IAM217, Its Second Wholly Owned AI-Discovered Candidate Read More
Sep 21, 2026 Iambic Launches Enchant v3 – Molecular Superintelligence Designed to Advance End-to-End Drug Discovery & Development Read More
Sep 21, 2026 AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery Read More